Pre-clinical data of GM1485 to be presented by GliaMed

Nov 18 2009

GliaMed, Inc., a development stage biopharmaceutical company, today announced that Dr. David Weinstein, chief scientific officer and company founder, will present pre-clinical data demonstrating acceleration of wound healing through the in vivo induction and recruitment of stem cells at the Stem Cells USA & Regenerative Medicine Congress in Washington, D.C.

The Company’s small molecule lead drug candidate, GM1485, has been shown to induce autologous stem cells in vivo and to regenerate a variety of damaged tissues. Successfully regenerated tissues include: neurons, cardiac tissue, cartilage, blood vessels and others.

GM1485 has the potential to revolutionize regenerative medicine. As opposed to current approaches which involve the expensive and time consuming processing and expansion of stem cells outside the body which are then implanted in the patient at the site of disease or trauma, GM1485 is in the form of a conventional medicine which can be administered orally, topically or parenterally.

“GM1485 has the promise of making stem cell therapy simple, inexpensive and widely available. By using a small molecule which exploits the body’s native regenerative mechanisms, it may be possible to more fully realize the potential of stem cell therapy,” said Dr. Weinstein.

GliaMed expects to begin human trials of GM1485 in early 2010.